Analysis of 2023 December China E-cigarette Exports to Switzerland

Industry Insight by 2FIRSTS Mincy
Mar.11.2024
Analysis of 2023 December China E-cigarette Exports to Switzerland
China's e-cigarette exports to Switzerland surged in December 2023, with a 72.18% monthly increase totaling $5.63 million.

According to the latest trade data released by the General Administration of Customs of the People's Republic of China, 2FIRSTS has compiled the e-cigarette export data from China to Switzerland in December 2023. The details are as follows:

Analysis of 2023 December China E-cigarette Exports to Switzerland
Image source: 2FIRSTS (Mincy graphics)

 

The export value reached approximately $5.63 million, showing a month-on-month increase of 72.18% and a year-on-year increase of 32.03%.

Analysis of 2023 December China E-cigarette Exports to Switzerland
Image source: 2FIRSTS (Mincy design)

 

The export volume is approximately 94 tons, an increase of 32.89% month-on-month and 56.90% year-on-year.

Analysis of 2023 December China E-cigarette Exports to Switzerland
Image source: 2FIRSTS (Mincy diagram)

 

The export unit price was $59.49 per kilogram, representing a 29.56% increase month-on-month and a 15.85% decrease year-on-year. The average price for "e-cigarettes and similar personal electronic vaporizing devices" was $13.93 per unit.

 

Analysis of 2023 December China E-cigarette Exports to Switzerland
Image source: 2FIRSTS (Mincy Mapping)

 

Among them, "e-cigarettes and similar personal electronic vaporizer devices" accounted for 38.58% of the export category, while "non-burning products containing nicotine without tobacco or reconstituted tobacco" accounted for 61.42%.

Analysis of 2023 December China E-cigarette Exports to Switzerland
Image source: 2FIRSTS (created by Mincy)

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Russian Vape Industry Proposes State Monopoly on E-Liquid Production as Alternative to Ban
Russian Vape Industry Proposes State Monopoly on E-Liquid Production as Alternative to Ban
Russian business groups are trying to persuade the authorities to abandon plans to ban the sale of e-cigarettes and related liquids at both the federal and regional levels.
Apr.03 by 2FIRSTS.ai
Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
Russian consumer group urges Kremlin administration to reject regional vape sales bans
Russian consumer group urges Kremlin administration to reject regional vape sales bans
A Russian consumer organization has urged the Presidential Administration to block proposals that would let regions ban ENDS and e-liquid sales, warning it would create fragmented regulation and turbocharge the illicit market. The group cites WHO statistics and overseas experiences to argue for a more targeted regulatory model.
Feb.06 by 2FIRSTS.ai
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
PMI Flags 2026 Headwinds from Japan Taxes, Sees Smoke-Free Growth Re-Accelerating Beyond in Earnings Call
PMI Flags 2026 Headwinds from Japan Taxes, Sees Smoke-Free Growth Re-Accelerating Beyond in Earnings Call
PMI said on its latest earnings call that Japan’s tax cycle will weigh on 2026 performance, while smoke-free growth is expected to re-accelerate thereafter. The discussion also covered U.S. regulation, ZYN strategy and AI-driven efficiency.
Feb.07